Leland W.K. Chung

About Leland W.K. Chung

There are very few effective medications for patients whose cancer has spread and metastasized to different parts of the body. XL184 (Cabozantinib) has shown promise in the remission of prostate cancer in bone and soft tissue metastases. This medication is known to target multiple critical cellular functions, thereby handicapping a tumor cell. Dr. Chung and his team will explore the mechanisms of action of XL184 in detail. The effects of combining this medication with other available therapies will also be evaluated. Further, the team will study the various cell death mechanisms switched off in XL184-treated cancer cells that lead to resistance and uncontrolled growth of tumors.
Potential patient benefit: The proposed studies will improve our understanding of the mechanism of action of XL184 and will identify combinative therapies to guide optimal use of this promising medication for better patient outcomes

Leland W.K . Chung, PhD –

Cedars-Sinai Medical Center
Targeting Cell Death Programs in the Tumor and its Microenvironment

Co-investigators:

Edwin Posadas, MD; Neil Bhowmick, PhD; Hyung L Kim, MD;
Andre Rogatko, PhD; Beatrice Knudsen, MD, PhD; Stuart Holden, MD; Mahul B. Amin, MD; Martin Gleave, MD; Michael Freeman, PhD; Daqing Wu, PhD; Matthew Bui, MD